Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction
Anthony Carnicelli(Duke University), Christopher B. Granger(Clinical Research Institute), Mauricio G. Cohen(Santa Ana College), Satoshi Yasuda(Tohoku University), Stuart Pocock(London School of Hygiene & Tropical Medicine), Karolina Andersson Sundell(AstraZeneca (Brazil)), Katarina Hedman(AstraZeneca (Brazil)), David Brieger(The University of Sydney), Shaun G. Goodman(University of Toronto), Dirk Westermann(University Medical Center Freiburg), José Carlos Nicolau(Hospital São Paulo), Tabassome Simon(Sorbonne Université), Ruth Owen(Spanish National Centre for Cardiovascular Research)
Cited by 7
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
|New England Journal of Medicine|2010|7.2k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
|New England Journal of Medicine|2011|6.4k
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
|New England Journal of Medicine|2019|4.8k